Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33110741
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
E-cigarette, or vaping, product use-associated lung injury: a review
#MMPMID33110741
Belok SH
; Parikh R
; Bernardo J
; Kathuria H
Pneumonia (Nathan)
2020[]; 12
(?): 12
PMID33110741
show ga
BACKGROUND: E-cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) is
a disease entity related to the use of battery-operated or superheating devices
that create an aerosolized form of nicotine and tetrahydrocannabinol (THC) and/or
other substances for inhalation. METHODS: We performed a literature review to
document epidemiology, pathogenesis and risk factors, diagnosis, clinical
presentation, evaluation and management of EVALI. RESULTS: In the summer of 2019,
an outbreak of EVALI cases brought this disease entity into the national
spotlight. Since being recognized as a serious pulmonary disease with public
health implications, more than 2600 cases have been reported to CDC with 68
deaths as of February 2020. The pathophysiology of EVALI remains unknown.
Substances such as Vitamin E acetate have been implicated as a possible causes of
lung injury. The CDC has established case definitions of "confirmed EVALI" cases
to help guide identification of the disease and assist in surveillance. While
clinical judgement by healthcare providers is imperative in the identification of
EVALI cases, the heterogeneous presentations of EVALI make this difficult as
well. Ultimately most investigative studies should be aimed at ruling out other
disease processes that can present similarly. Treatment is centered around
removing the offending substance and providing supportive care. CONCLUSIONS:
EVALI is a serious pulmonary disease with public health implications. Diagnosis
requires a high degree of suspicion to diagnose and exclusion of other possible
causes of lung disease. It may be beneficial to involve a pulmonary specialist
early in the management of this disease which is generally supportive care.
free
free
free
